Search Results
Firefighters and Cancer Risk
Firefighters are at an increased risk of developing cancer. There are steps to take that can reduce that risk.All firefighters, regardless whether they are career or volunteer, put their own lives at risk to save others in their communities. In addition to the danger of putting out fires, firefighters are at an increased risk for different types of cancer due to the smoke and hazardous chemicals they are exposed to in the line of duty. There have been multiple studies that show this increased risk for cancer.
Prevention of myeloid cancers by understanding their pre-clinical evolution
Here we propose to study blood DNA from 1500 people who have had extensive genetic and aging-related tests over many years as participants of the "Immunoageing" study (<a href="http://www.immunoageing.eu/index.html">http://www.immunoageing.eu/index.html</a>). We propose to study these people for the presence of age-related clonal hematopoiesis (ARCH) to understand what factors are associated with ARCH and its expansion.Understanding Blood, Marrow and the Lymphatic System
Understanding your diagnosis will help you make informed decisions about your treatment, and give you a greater understanding of the scientific advances in blood cancer treatment and improvements in quality of life for survivors.
Knowing about normal blood and marrow and the lymphatic system can also help you better understand your diagnosis.
211Astatine-CD123 Radioimmunotherapy for Cancer (Stem) Cell-Directed Treatment of Acute Leukemia
Because acute leukemias are very sensitive to radiation, radioisotopes are ideal payloads to arm antibodies against these difficult-to-cure, aggressive blood cancers. Here, we will develop fully human anti-CD123 antibodies carrying the highly potent alpha-emitter astatine-211 (211At) as a new therapy for acute leukemia.Long-Term and Late Effects For Cancer Survivors
Blood cancer survivors don't always have serious long-term or late effects of treatment. For those who do, some long-term effects, such as fatigue, can linger for months or years after therapy. Late effects, such as medical conditions like heart disease and other cancers, don't appear until years after treatment ends. Effects can range from mild to severe.
Talk with your doctor about possible long-term and late effects. Your risk for developing long-term or late effects can be influenced by your:
Follow-Up Care For Childhood Cancer Survivors
Survivorship WorkbookUse this Survivorship Workbook to collect all the important information you need throughout diagnosis, treatment, follow-up care and long-term management of a blood cancer.
Targeting aberrant epigenetic condensates in myeloid malignancies
Genetic changes of ASXL1 are very frequent in human blood cancers. We found that the altered forms of ASXL1 protein promote blood cancers through forming tiny liquid-like droplets in the cell. In this project, we aim to develop a method to specifically break these droplets to inhibit its activity in driving blood cancers.Uncovering the role of TCL1A as a driver of clonal hematopoiesis and hematological malignancies
Mutations in a diverse set of genes can lead to pre-cancerous expansion of blood stem cells, but the factors that mediate the growth of these mutant clones are unknown. We recently discovered that many of these mutations lead to abnormal activation of a gene called TCL1A. Consequently, TCL1A may be an attractive target for treating or preventing blood cancers, but little is known about its function. Here, we will uncover how TCL1A influences the biology of pre-cancerous blood stem cells.Long-Term And Late Effects Of Treatment For Childhood Cancer Survivors
Treatment for childhood blood cancer may consist of chemotherapy and other drug therapies and may also include radiation therapy or allogeneic stem cell transplantation. There are risks for long-term and late effects common to all of these treatments, and these may include problems with learning, fatigue, bone or joint pain and an increased risk for developing a secondary cancer.
Health Insurance and End-of-Life Care for People with Hematologic Malignancies
Patients with blood cancers from racial and ethnic minority groups are more likely to experience suboptimal end-of-life (EOL) care. These disparities may be partially driven by health insurance differences but there is limited research examining insurance access as a potential contributor to EOL care disparities for this population. We will leverage complementary local and national datasets to assess the relationship between insurance status and type with EOL quality measures.Unfolding selective pathway dependencies of CALR mutated myeloproliferative neoplasms
The goal of this study is to selectively eradicate blood cancer cells carrying mutations in a gene called calreticulin. Genes and corresponding proteins required for cancer cell survival but not for the survival of healthy cells will first be targeted in mice, both genetically and by using drugs. Validated drugs will then be tested on patient samples. This study will lay the foundation to the development of tailored treatments for patients with calreticulin-mutated blood cancer.Advancing the therapeutic landscape for Chronic Myelomonocytic Leukemia (CMML)
CMML is a universally lethal blood cancer characterized by increased monocytes (a type of white blood cell) in the peripheral blood and abnormal appearing cells within the bone marrow. Most CMML patients are clinically asymptomatic and remain so for weeks to months following diagnosis, with disease progression remaining inevitable. Despite therapeutic advances in similar blood cancers, no specific molecularly targeted therapies currently exist to treat CMML.Predicting progression in myeloproliferative neoplasm patients by reconstructing the history of disease in each patient
Blood cancers called myeloproliferative neoplasms occur when one of the blood stem cells picks up a mutation. Some patients stay in the chronic phase of the disease for years whereas others rapidly progress with poor outcome. We recently measured when the cancer mutation first occurs and the rate of expansion of the cancer cells in individual patients. We will develop a method that uses the history of disease in each patient to identify those that are at risk of progression.Genomic interrogation of high-risk myeloid neoplasms to identify new therapies
The long-term goal of my research program is to improve the outcomes for patients with high-risk myeloid blood cancers, particularly those with loss of chromosome 7 or CUX1. We are tackling this question using an arsenal of innovative methods and tools, including mouse models, human cells and patient samples, and state-of-the-art technologies to examine the cancer cell genome. Accomplishing this work will reveal new treatments and strategies for preventing blood cancers from arising.CHEK2 as a predisposition gene for clonal hematopoiesis and hematopoietic malignancies
This proposal explores how inherited mutations in the DNA repair gene CHEK2 lead to blood cancers. Our work employs two unique resources: patient-derived cell lines and mice engineered with an inherited Chek2 variant that accurately models how bone marrow stem cells acquire DNA changes over time leading to bone marrow cancers. Our results may lead to new approaches that slow or prevent blood cancers in people with high risk.Development of mutant GTPase-specific degraders for peripheral T cell lymphoma treatment
This project aims to develop targeted therapies against peripheral T cell lymphoma (PTCL), a diverse group of aggressive blood cancers with poor clinical outcomes. This project is tightly relevant to cancer control and treatment, promising to advance our understanding on how blood cancers initiate and progress, and lead to new therapeutics for the treatment of peripheral T cell lymphoma (PTCL). We will develop targeted therapeutics to engage an oncogenic RHOA GTPase mutant to treat PTCL and other types of tumors with similar genetic backgrounds.Fertility and Pregnancy
In addition to our programs and services for blood cancer patients, families and caregivers, The Leukemia & Lymphoma Society (LLS) is pleased to offer an extensive directory of national and international resources. These organizations can help with cancer-related issues like financial assistance, support and counseling, assistance with transportation, and summer camps.
Patient Experience Research and Palliative Care Integration in Malignant Hematology
My research aims to improve the patient and caregiver experience of blood cancer care. To achieve this, I conduct trials of integrated palliative care interventions. Palliative care improves patient and caregiver outcomes for those with solid tumors, but less is known about its role in hematology. My research aims to design and implement integrated palliative care interventions in blood cancer settings, to improve the patient and caregiver experience of illness, regardless of treatment outcome.Overcoming ibrutinib resistance in mantle cell lymphoma
Mantle cell lymphoma (MCL) is an aggressive blood cancer which affects about 3,000 individuals in the United States annually. Despite advances of novel therapies in blood cancers, MCL remains incurable, and patients ultimately succumb to disease. We seek to evaluate longitudinal samples from patients with MCL treated with novel therapies to understand the mechanisms of drug resistance. We identify novel targets, with a particular focus on protein turnover pathways, to overcome drug resistance and improve survival of patients with MCL.Patient Well-Being During Treatment
In addition to our programs and services for blood cancer patients, families and caregivers, The Leukemia & Lymphoma Society (LLS) is pleased to offer an extensive directory of national and international resources. It may be helpful for you to browse each section to discover all that's offered.
Professional Organizations for Health Care Providers
In addition to our programs and services for blood cancer patients, families and caregivers, The Leukemia & Lymphoma Society (LLS) is pleased to offer an extensive directory of national and international resources. It may be helpful for you to browse each section to discover all that's offered.
Related Diseases and Conditions
In addition to our programs and services for blood cancer patients, families and caregivers, The Leukemia & Lymphoma Society (LLS) is pleased to offer an extensive directory of national and international resources. It may be helpful for you to browse each section to discover all that's offered.